Publication

Article

BioPharm International

BioPharm International-06-02-2003
Volume2003 Supplement
Issue 1

Part 5: Disinfection

Author(s):

Gail Sofer

by Gail Sofer, BioReliance

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue
Part 1: Skin, Bone, and Cells
BioPharm International's Virus Inactivation Series: A Preface
Part 4: Culture Media, Biotechnology Products, and Vaccines
Inactivation of Viruses: An Introduction to the Series
Part 3b: Plasma and Plasma Products (Treatments Other than Heat or Solvent/Detergent)
Part 6: Inactivation Methods Grouped by Virus

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!
Related Videos
Behind the Headlines, Episode 23: Patent Cliff Deals, Tariff Pressures, and the In Vivo Cell Therapy Bet
Related Content
Gene Therapy for Cancer Treatment Concept Cancer therapy with T-cell and pipette | Image Credit: © catalin - © catalin - stock.adobe.com
September 9th 2025

€10.7 Million Investment Accelerates Gene Writing and CAR-T Preclinical Development

Feliza Mirasol
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
September 9th 2025

The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game

G-CON
Lymphocytes such as T cells, B cells are part of the immune system | Image Credit: © Artur - © Artur - stock.adobe.com
September 9th 2025

The Manufacturing Journey of CAR-T Cellular Therapy—An Overview

Shada Warreth
Mastering Antibody-Drug Conjugates
September 9th 2025

Mastering Antibody-Drug Conjugates

BIOVECTRA
Doctor technology AI integrates big data analytics with clinical research, enabling precise treatment plans tailored to individual patient needs and genetic profiles. | Image Credit: © Suriyo - stock.adobe.com
September 9th 2025

Agentic AI Collaborative Initiative Announced by Pistoia Alliance

Patrick Lavery
Background with viruses. Adeno-associated virus serotype 1. Virus is used as a vector for gene therapy. A model is built using data of viral macromolecular structure from Protein Data Bank (PDB 3NG9) | Image Credit: © Dr_Microbe - © Dr_Microbe - stock.adobe.com
September 9th 2025

AAV Manufacturing Partnership Supports Gene Therapy for CLN2 Batten Disease

Feliza Mirasol
© 2025 MJH Life Sciences

All rights reserved.